Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Crinetics Pharmaceuticals Inc.
Headquarters: San Diego, CA, United States of America
Website: https://crinetics.com/
Year Founded: 2008
Status: Public
Industry Sector: HealthTechnology
CEO: Scott R. Struthers, PhD
Number Of Employees: 437
Enterprise Value: $2,827,587,790
PE Ratio: -9.46
Exchange/Ticker 1: NASDAQ:CRNX
Exchange/Ticker 2: N/A
Latest Market Cap: $3,260,419,328
BioCentury | Feb 25, 2025
Management Tracks
After leaving FDA, Cavazzoni joins Pfizer as CMO
Plus: CFO hires at Nuclera, Crinetics, Terns and updates from Xeris, Inhibikase and Climb Bio
BioCentury | Dec 17, 2024
Management Tracks
Bruce Cozadd to retire as Jazz’s CEO
Plus: James Li named venture partner at Frazier, and updates from Crinetics, NeoPhore, VectorY and more
BioCentury | Oct 11, 2024
Finance
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception
BioCentury’s weekly Public Equity Report also includes financings by Crinetics, Scholar Rock, Immatics, Inhibikase and Vicore
BioCentury | Oct 10, 2024
Finance
Down rounds don’t aid post-IPO performance
Neither private down rounds nor IPO step-downs correlate with market performance after IPOs
BioCentury | Mar 19, 2024
Product Development
Clinical report: Crinetics ready to advance oral acromegaly therapy to FDA
Plus: Phase IIb setback for Spruce, Inventiva combination in MASH, and more
BioCentury | Mar 1, 2024
Finance
Public equity report: PIPEs, follow-ons for 11 biotechs add up to $3B+
Viking, Celldex, Janux offerings top list of follow-ons; Denali, Crinetics, Avidity among those raising PIPEs
BioCentury | Dec 20, 2023
Deals
Dec. 19 Quick Takes: Ionis, Otsuka in European deal for HAE therapy
Plus: Carmot spinout Kimia raises $55M series A round, CureVac tumbles on loss in patent case and more from Lassen, Atavistik, Crinetics, Merck and CSL
BioCentury | Sep 14, 2023
Regulation
Sept. 13 Quick Takes: Madrigal gets March PDUFA date for NASH therapy
Plus: Rocket parlays gene therapy update into $175M raise and updates from DalCor, Mironid, Crinetics, Shionogi, Hasten, Dewpoint and Orchid
BioCentury | Sep 11, 2023
Deals
Sept. 11 Quick Takes: Surprise miss for Acelyrin in hidradenitis suppurativa
Plus: Moderna, Immatics in oncology discovery, development deal, and updates from Takeda, Novartis, Crinetics, Verona, Nestlé
BioCentury | Oct 4, 2022
Management Tracks
Sause named CEO of Roche Diagnostics
Plus Kranzler becomes CEO of Urica, and updates from Pharus, Celularity, Cerevance and more
Items per page:
1 - 10 of 31